TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MSTR
Strategy
-- 304.000 SOFI
SoFi Technologies
-- 12.870 
NEWS
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response rate (44% in KRAS mutant, 17% in KRAS wild-type)
- Median progression-free survival of 12.9 months (22 months in KRAS mutant)
- Disease control rate at 6+ months: 61%overall (70% KRAS mutant, 50% KRAS wild-type)
- Generally well-tolerated with 10% discontinuation rate due to adverse events
Verastem plans to complete NDA submission in October 2024 for adult patients with recurrent KRAS mutant LGSOC, seeking Accelerated Approval and Priority Review from the FDA. The company aims to bring the first FDA-approved treatment for this specific indication to market in 2025.
- 31% overall response rate (44% in KRAS mutant, 17% in KRAS wild-type)
- Median progression-free survival of 12.9 months (22 months in KRAS mutant)
- Disease control rate at 6+ months: 61%overall (70% KRAS mutant, 50% KRAS wild-type)
- Generally well-tolerated with 10% discontinuation rate due to adverse events
Verastem plans to complete NDA submission in October 2024 for adult patients with recurrent KRAS mutant LGSOC, seeking Accelerated Approval and Priority Review from the FDA. The company aims to bring the first FDA-approved treatment for this specific indication to market in 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment